![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMEM5 |
Gene summary for TMEM5 |
![]() |
Gene information | Species | Human | Gene symbol | TMEM5 | Gene ID | 10329 |
Gene name | ribitol xylosyltransferase 1 | |
Gene Alias | HP10481 | |
Cytomap | 12q14.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | G3V1K2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10329 | TMEM5 | C06 | Human | Oral cavity | OSCC | 9.32e-04 | 6.98e-01 | 0.2699 |
10329 | TMEM5 | C07 | Human | Oral cavity | OSCC | 2.53e-09 | 1.20e+00 | 0.2491 |
10329 | TMEM5 | C08 | Human | Oral cavity | OSCC | 2.36e-37 | 8.03e-01 | 0.1919 |
10329 | TMEM5 | C09 | Human | Oral cavity | OSCC | 2.69e-07 | 3.13e-01 | 0.1431 |
10329 | TMEM5 | LN46 | Human | Oral cavity | OSCC | 2.16e-07 | 4.28e-01 | 0.1666 |
10329 | TMEM5 | LP15 | Human | Oral cavity | LP | 3.76e-05 | 8.78e-01 | 0.2174 |
10329 | TMEM5 | SYSMH2 | Human | Oral cavity | OSCC | 5.05e-16 | 4.63e-01 | 0.2326 |
10329 | TMEM5 | SYSMH3 | Human | Oral cavity | OSCC | 7.16e-23 | 5.59e-01 | 0.2442 |
10329 | TMEM5 | SYSMH6 | Human | Oral cavity | OSCC | 1.46e-05 | 2.59e-01 | 0.1275 |
10329 | TMEM5 | P1_cSCC | Human | Skin | cSCC | 3.78e-14 | 5.63e-01 | 0.0292 |
10329 | TMEM5 | P2_cSCC | Human | Skin | cSCC | 4.52e-11 | 3.54e-01 | -0.024 |
10329 | TMEM5 | P4_cSCC | Human | Skin | cSCC | 1.51e-16 | 3.90e-01 | -0.00290000000000005 |
10329 | TMEM5 | P10_cSCC | Human | Skin | cSCC | 3.35e-17 | 5.24e-01 | 0.1017 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
GO:00098969 | Breast | Precancer | positive regulation of catabolic process | 48/1080 | 492/18723 | 2.62e-04 | 3.84e-03 | 48 |
GO:00313319 | Breast | Precancer | positive regulation of cellular catabolic process | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
GO:19043757 | Breast | Precancer | regulation of protein localization to cell periphery | 15/1080 | 125/18723 | 5.58e-03 | 4.07e-02 | 15 |
GO:19054757 | Breast | Precancer | regulation of protein localization to membrane | 19/1080 | 175/18723 | 5.98e-03 | 4.22e-02 | 19 |
GO:00516047 | Breast | Precancer | protein maturation | 28/1080 | 294/18723 | 6.45e-03 | 4.50e-02 | 28 |
GO:19030767 | Breast | Precancer | regulation of protein localization to plasma membrane | 13/1080 | 104/18723 | 6.79e-03 | 4.65e-02 | 13 |
GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
GO:000989614 | Breast | IDC | positive regulation of catabolic process | 62/1434 | 492/18723 | 7.06e-05 | 1.42e-03 | 62 |
GO:190547513 | Breast | IDC | regulation of protein localization to membrane | 28/1434 | 175/18723 | 1.56e-04 | 2.71e-03 | 28 |
GO:003133114 | Breast | IDC | positive regulation of cellular catabolic process | 54/1434 | 427/18723 | 1.85e-04 | 3.07e-03 | 54 |
GO:190307613 | Breast | IDC | regulation of protein localization to plasma membrane | 17/1434 | 104/18723 | 2.28e-03 | 2.09e-02 | 17 |
GO:190437513 | Breast | IDC | regulation of protein localization to cell periphery | 19/1434 | 125/18723 | 3.06e-03 | 2.60e-02 | 19 |
GO:005160413 | Breast | IDC | protein maturation | 35/1434 | 294/18723 | 6.18e-03 | 4.40e-02 | 35 |
GO:00726599 | Breast | IDC | protein localization to plasma membrane | 34/1434 | 284/18723 | 6.33e-03 | 4.47e-02 | 34 |
GO:004586123 | Breast | DCIS | negative regulation of proteolysis | 63/1390 | 351/18723 | 4.39e-11 | 6.06e-09 | 63 |
GO:000989624 | Breast | DCIS | positive regulation of catabolic process | 61/1390 | 492/18723 | 5.32e-05 | 1.09e-03 | 61 |
GO:003133124 | Breast | DCIS | positive regulation of cellular catabolic process | 54/1390 | 427/18723 | 8.34e-05 | 1.58e-03 | 54 |
GO:190547522 | Breast | DCIS | regulation of protein localization to membrane | 26/1390 | 175/18723 | 5.31e-04 | 6.88e-03 | 26 |
GO:190307623 | Breast | DCIS | regulation of protein localization to plasma membrane | 16/1390 | 104/18723 | 4.13e-03 | 3.27e-02 | 16 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM5 | SNV | Missense_Mutation | novel | c.1220N>C | p.Lys407Thr | p.K407T | Q9Y2B1 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM5 | SNV | Missense_Mutation | c.287N>T | p.Thr96Ile | p.T96I | Q9Y2B1 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
TMEM5 | SNV | Missense_Mutation | novel | c.739G>A | p.Ala247Thr | p.A247T | Q9Y2B1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM5 | SNV | Missense_Mutation | novel | c.239G>A | p.Arg80Lys | p.R80K | Q9Y2B1 | protein_coding | tolerated(0.38) | benign(0.009) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM5 | SNV | Missense_Mutation | rs570064856 | c.154G>C | p.Glu52Gln | p.E52Q | Q9Y2B1 | protein_coding | tolerated(0.39) | benign(0.221) | TCGA-VS-A9UU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMEM5 | SNV | Missense_Mutation | c.559N>G | p.Leu187Val | p.L187V | Q9Y2B1 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TMEM5 | SNV | Missense_Mutation | c.559N>G | p.Leu187Val | p.L187V | Q9Y2B1 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
TMEM5 | SNV | Missense_Mutation | novel | c.724N>C | p.Trp242Arg | p.W242R | Q9Y2B1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TMEM5 | SNV | Missense_Mutation | novel | c.1133N>T | p.Ser378Phe | p.S378F | Q9Y2B1 | protein_coding | deleterious(0.02) | possibly_damaging(0.568) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM5 | SNV | Missense_Mutation | novel | c.316G>A | p.Ala106Thr | p.A106T | Q9Y2B1 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |